Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aquestive Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$52.23M. For fiscal 2025 it was -$70.50M. The highest annual figure on record is $3.64M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$70.50M | – |
| FY2024 | Dec 31, 2024 | -$30.05M | – |
| FY2023 | Dec 31, 2023 | -$13.76M | – |
| FY2022 | Dec 31, 2022 | -$39.68M | – |
| FY2021 | Dec 31, 2021 | -$31.72M | – |
| FY2020 | Dec 31, 2020 | -$39.45M | – |
| FY2019 | Dec 31, 2019 | -$49.76M | – |
| FY2018 | Dec 31, 2018 | -$45.70M | -1356.5% |
| FY2017 | Dec 31, 2017 | $3.64M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.23M | -4418.5% |
| Q1 FY2025 | Mar 31, 2025 | -$19.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.13M | – |
| Q2 FY2024 | Jun 30, 2024 | $260.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.10M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.94M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.78M | -584.5% |
| Q1 FY2021 | Mar 31, 2021 | -$7.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.13M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.26M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.93M | -257.7% |
| Q1 FY2019 | Mar 31, 2019 | -$12.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.55M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.30M | – |
| Q3 FY2017 | Sep 30, 2017 | $11.37M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.12M | – |
See a number that looks wrong?